Abstract
Prostate cancer is the most frequently diagnosed non-cutaneous cancer and the second leading cause of cancer death in the male population in the USA and other developed nations. Initially, prostate cancer is dependent on androgens for growth, which provides a basis for using androgen deprivation therapy to treat locally advanced or metastatic disease. However, prostate cancer almost always progresses to a castration-resistant phenotype for which few treatment options with improved overall survival are available at present. Multiple studies have shown that active androgen receptor (AR) signaling is still required for development, growth, and progression of castration-resistant prostate cancer (CRPC). Thus, targeting AR signaling, particularly androgen-independent activation of AR signaling, in CRPC may result in novel therapeutic strategies. In this chapter, we summarize recent findings on the regulation of AR signaling by histone deacetylase 6 (HDAC6) and discuss the potential mechanisms by which HDAC6 influences androgen signaling in prostate cancer. We also discuss the potential of targeting HDAC6 in prostate cancer treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092
Damber JE, Aus G (2008) Prostate cancer. Lancet 371:1710–1721
Maluf FC, Smaletz O, Herchenhorn D (2012) Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo) 67:389–394
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240
Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R et al (2004) Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60:257–271
Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008–1013
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-Âresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Diaz M, Patterson SG (2004) Management of androgen-independent prostate cancer. Cancer Control 11:364–373
Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179
Massard C, Fizazi K (2011) Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876–3883
Labrie F (2004) Adrenal androgens and intracrinology. Semin Reprod Med 22:299–309
Denmeade SR, Lin XS, Isaacs JT (1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28:251–265
Maitland NJ, Collins AT (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26:2862–2870
Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–1490
Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-Ârefractory prostate cancer. J Natl Cancer Inst 93:1687–1697
Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M (2003) Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res 63:5622–5628
Huang ZQ, Li J, Wong J (2002) AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16:924–937
Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH et al (2006) Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408–1423
Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253–8261
Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483–490
van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W et al (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189–193
Small EJ, Ryan CJ (2006) The case for secondary hormonal therapies in the chemotherapy age. J Urol 176:S66–S71
Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892–2898
Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Mechanisms of endocrine therapy-Âresponsive and -unresponsive prostate tumours. Endocr Relat Cancer 12:229–244
Picard D, Yamamoto KR (1987) Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J 6:3333–3340
Pratt WB, Galigniana MD, Morishima Y, Murphy PJ (2004) Role of molecular chaperones in steroid receptor action. Essays Biochem 40:41–58
Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Anti-Âandrogens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31:2393–2399
Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY et al (1999) Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J Med 48:87–92
De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL et al (2011) Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 108:11878–11883
Dehm SM, Tindall DJ (2007) Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21:2855–2863
Moore TW, Mayne CG, Katzenellenbogen JA (2010) Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24:683–695
Saporita AJ, Ai J, Wang Z (2007) The Hsp90 inhibitor, 17-AAG, prevents the Âligand-Âindependent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509–520
Hoimes CJ, Kelly WK (2010) Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol 2:107–123
Kovacs JJ, Cohen TJ, Yao TP (2005) Chaperoning steroid hormone signaling via reversible acetylation. Nucl Recept Signal 3:e004
Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM (2010) FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol 30:1243–1253
DeFranco DB, Ramakrishnan C, Tang Y (1998) Molecular chaperones and subcellular trafficking of steroid receptors. J Steroid Biochem Mol Biol 65:51–58
Manninen T, Purmonen S, Ylikomi T (2005) Interaction of nuclear receptors with hsp90 in living cells. J Steroid Biochem Mol Biol 96:13–18
Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306–360
Finkel T, Duc J, Fearon ER, Dang CV, Tomaselli GF (1993) Detection and modulation in vivo of helix-loop-helix protein-protein interactions. J Biol Chem 268:5–8
Pratt WB (1993) The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 268:21455–21458
Smith DF, Toft DO (1993) Steroid receptors and their associated proteins. Mol Endocrinol 7:4–11
Neckers L (2002) Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8:962–966
Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824–11831
Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW (1994) Derivation of androgen-Âindependent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57:406–412
Bertos NR, Wang AH, Yang XJ (2001) Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol 79:243–252
Fischle W, Kiermer V, Dequiedt F, Verdin E (2001) The emerging role of class II histone deacetylases. Biochem Cell Biol 79:337–348
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601–607
Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer. J Biomed Biotechnol 2011:875824
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749
Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19:286–293
Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96:4868–4873
Mahlknecht U, Schnittger S, Landgraf F, Schoch C, Ottmann OG, Hiddemann W et al (2001) Assignment of the human histone deacetylase 6 gene (HDAC6) to X chromosome p11.23 by in situ hybridization. Cytogenet Cell Genet 93:135–136
Verdel A, Khochbin S (1999) Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J Biol Chem 274:2440–2445
Boyault C, Sadoul K, Pabion M, Khochbin S (2007) HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26:5468–5476
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738
Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J et al (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27:197–213
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D et al (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21:6820–6831
Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB (2005) Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 280:33792–33799
Aoyagi S, Archer TK (2005) Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15:565–567
Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729–26734
Kekatpure VD, Dannenberg AJ, Subbaramaiah K (2009) HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 284:7436–7445
Basak S, Pookot D, Noonan EJ, Dahiya R (2008) Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 7:3195–3202
Fang Y, Fliss AE, Robins DM, Caplan AJ (1996) Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271:28697–28702
Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB et al (2009) HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-Âresistant prostate cancer. Mol Endocrinol 23:1963–1972
Guardiola AR, Yao TP (2002) Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277:3350–3356
Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C (1997) Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 129:17–26
Hager GL, Lim CS, Elbi C, Baumann CT (2000) Trafficking of nuclear receptors in living cells. J Steroid Biochem Mol Biol 74:249–254
Nakauchi H, Matsuda K, Ochiai I, Kawauchi A, Mizutani Y, Miki T et al (2007) A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines. J Histochem Cytochem 55:535–544
Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818
Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I et al (1995) Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796–803
Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M et al (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop Ânormally. Mol Cell Biol 28:1688–1701
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K et al (2007) An Âacetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25:151–159
Gibbs A, Schwartzman J, Deng V, Alumkal J (2009) Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA 106:16663–16668
Chen L, Meng S, Wang H, Bali P, Bai W, Li B et al (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4:1311–1319
Culig Z (2004) Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22:179–184
Kaarbo M, Klokk TI, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29:1227–1238
Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ (2008) HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 283:12686–12690
Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R et al (2007) HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 120:1469–1479
Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F et al (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769–774
Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V (2004) Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 48:273–290
Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ et al (2009) Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol 92:125–132
Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T et al (2008) The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68:7561–7569
Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18:291–297
Wu Y, Song SW, Sun J, Bruner JM, Fuller GN, Zhang W (2010) IIp45 inhibits cell migration through inhibition of HDAC6. J Biol Chem 285:3554–3560
Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R (2010) CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 29:131–144
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39
Wagner JM, Hackanson B, Lubbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1:117–136
Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958–966
Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA et al (2007) Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell Âproliferation. Mol Cancer Ther 6:51–60
Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB (2006) Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-Âpositive prostate cancer cells. Mol Cancer Res 4:113–123
Ambrosini GL, de Klerk NH, Fritschi L, Mackerras D, Musk B (2008) Fruit, vegetable, vitamin a intakes, and prostate cancer risk. Prostate Cancer Prostatic Dis 11:61–66
Cohen JH, Kristal AR, Stanford JL (2000) Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92:61–68
Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al (2000) Vegetables, fruits, legumes and prostate cancer: a multiethnic case–control study. Cancer Epidemiol Biomarkers Prev 9:795–804
Kristal AR, Lampe JW (2002) Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer 42:1–9
Myzak MC, Karplus PA, Chung FL, Dashwood RH (2004) A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64:5767–5774
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Mayo Clinic
About this chapter
Cite this chapter
Ai, J., Wang, Z. (2013). HDAC6 Regulation of Androgen Signaling in Prostate Cancer. In: Tindall, D. (eds) Prostate Cancer. Protein Reviews, vol 16. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6828-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6828-8_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6827-1
Online ISBN: 978-1-4614-6828-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)